No Detail Found!

Formulation Development and Six Sigma Assessment of Meloxicam (5mg) Orally Disintegrating Minitablets (ODMTs) from Coprocessed Excipients

Author(s)
Riffat Yasmin Department of Pharmaceutics, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
Wajiha Iffat Department of Pharmaceutical Chemistry, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
Farya Zafar Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Durriya Hashmat Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Rizwana Rahmat Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Mahwish Akhtar Department of Pharmaceutical Chemistry, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
Huma Ali Department of Pharmaceutics, Institute of Pharmaceutical Sciences, Jinnah Sind Medical University, Karachi, Pakistan.
Abstract
Background: Geriatric and dysphagic patients experience difficulty in swallowing conventional tablets, highlighting the need to design for patientfriendly dosage forms. This study aimed to develop Orally Disintegrating Minitablets (ODMTs) of Meloxicam using coprocessed excipients (CPEs) and to validate the manufacturing process through Six Sigma methodology. Methods: Three Meloxicam (5 mg) ODMT formulations (FF-MC, FF-MM, PFT) were prepared by direct compression using different CPEs (F-melt® C, F-melt® M and Pearlitol® Flash). Pre- and post-compression evaluations included flow properties, hardness, friability, disintegration time, wetting time, drug content, and in-vitro dissolution. Process capability of the best formulation FF-MM was assessed in Minitab® 22.x using Cp, Cpk, Pp, and Ppk indices for key quality attributes. Results: All formulations met pharmacopeial standards. FF-MM showed superior performance, with a disintegration time of 16.1± 1.03s, wetting time of 12.6±0.51s, hardness of 25.07 ±0.70 N, friability of 0.22±0.082, assay of 100.16±0.06 and 95.32±0.87% drug release within 15 min. Weibull kinetic model of drug release was followed by trial formulations. Accelerated stability testing results were found satisfactory for all formulations. Six Sigma analysis demonstrated that manufacturing process of formulation FF-MM identified as capable with high potential. Conclusion: Meloxicam ODMTs formulated with CPEs presented a promising patient-centric option for improved arthritis management among geriatrics. The integration of Six Sigma tools confirmed the manufacturing robustness of the optimal formulation (FF-MM), supporting its potential translation from development to industrial scale-up.
Publication Details
Page(s) 189-205
DOI DOI not available
Published Journal: RADS Journal of Pharmacy and Allied Health Sciences, Volume: 3, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Coprocessed excipients (CPEs), Six sigma, Microcrystalline cellulose (MCC), Active pharmaceutical ingredient (API)
References
Ashiq K. .2023 .An updated review on rheumatoid arthritis (RA): Epidemiology, pathophysiology, diagnosis, and the current approaches for its treatment. Sudan Journal of Medical Sciences, 18(4) : 51-51.
Khaliq T. .2020 .Clinical profile and treatment outcomes of patients with rheumatoid arthritis at a tertiary care hospital of Pakistan. , 43 : 03.
Shakil M. .2021 .Clinical and hematological parameters in patients of Rheumatoid arthritis in a tertiary care hospital. Rawal Medical Journal, 46(1) : 45-47.
Aletaha D. .2018 .Diagnosis and management of rheumatoid arthritis: a review. J Jama, 320(13) : 1360-72.
Khalil N.Y.,Meloxicam N.Y. .2020 .Profiles of drug substances, excipients and related methodology. Elsevier, : 159-97.
Emam M.F. .2021 .Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability. J Drug Development Industrial Pharmacy, 47(1) : 163-75.
da-Silveira L.M. .2018 .Drug-excipient compatibility assessment of solid formulations containing meloxicam. European Journal of Pharmaceutical Sciences, 112 : 146-51.
Weyna D.R. .2012 .Improving solubility and pharmacokinetics of meloxicam via multiplecomponent crystal formation. J Molecular pharmaceutics, 9(7) : 2094-102.
Khan K.U. .2021 .Synthesis of PEG-4000-copoly (AMPS) nanogels by cross-linking polymerization as highly responsive networks for enhancement in meloxicam solubility. Drug Development Industrial Pharmacy, 47(3) : 465-76.
Parekh V.J. .2017 .Self nanoemulsifying granules (SNEGs) of meloxicam: preparation, characterization, molecular modeling and evaluation of in vivo anti-inflammatory activity. J Drug Development Industrial Pharmacy, 43(4) : 600-10.
.2003 .Stability testing guidelines: stability testing of new drug substances and products. ICH Steering Committee, : 1-24.
Aleksovski A. .2015 .Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. J Expert opinion on drug delivery, 12(1) : 65-84.
Stoltenberg I. .2011 .Orally disintegrating minitablets (ODMTs)-a novel solid oral dosage form for paediatric use. European journal of pharmaceutics biopharmaceutics, 78(3) : 462-9.
Abdelmonem R. .2021 .Formulation and evaluation of baclofen-meloxicam orally disintegrating tablets (ODTs) using co-processed excipients and improvement of ODTs performance using six sigma method. J Drug Design, Development Therapy, : 4383-402.
Chow K. .2008 .Engineering of pharmaceutical materials: An industrial perspective. Journal of pharmaceutical sciences, 97(8) : 2855-77.
Saha S. .2009 .Multifunctional coprocessed excipients for improved tabletting performance. Expert opinion on drug delivery, 6(2) : 197-208.
Garg A. .2013 .Mouth dissolving tablets: a review. J Journal of Drug Delivery Therapeutics, 3(2) : .
Kumbhar P. .2023 .QbD and Six Sigma quality approach for chromatographic estimation of repurposed simvastatin from nanostructured lipid carriers. Microchemical Journal, 185 : 108310.
Mishra S.M. .2017 .An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine. Pharmaceutical development Technology, 22(7) : 889-903.
Seenivasan R. .2024 .Optimizing Metformin HCl manufacturing: A Six Sigma approach to assess process capability. Journal of Applied Pharmaceutical Science, 14(8) : 103-11.
Nisa A.N. .2021 .Determining the release kinetics of risperidone controlled release matrices to treat Schizophrenia. Pak J of Pharm Sci, 43(9) : 1925-34.
Moqbel H.A. .2016 .A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation. Drug Delivery, 23(8) : 2998-3007.
Fouad S.A. .2020 .Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug for enhanced dissolution: in-vitro optimization/in-vivo evaluation. J PLoS One, 15(12) : e0244646.
Khan M.A.A. .2022 .. Formulation Development and Evaluation of Oro-Dispersible Tablets Based On Solid Dispersion of Cimetidine. Journal of Drug Delivery Therapeutics, 12 : 42-6.
Akhtar H. .2023 .Quality-by-design based development of fast dispersible nimodipine tablets: Formulation attributes and release kinetic assessment. Pak J of Pharm Sci, 36(2) : .
Higuchi T. J. J. O. P. S. .1963 .Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of pharmaceutical sciences, 52(12) : 1145-1149.
Costa P. .2001 .Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 0987(01) : 11297896-24.
. .United States Pharmacopeia 35th Revision-National Formulary 30th Edition USP. Rockville, : 3793-4.
Bowles B.J. .2018 .Co-processed excipients for dispersible tablets-part 1: Manufacturability. J AAPS PharmSciTech, 19 : 2598-609.
Dziemidowicz K. .2018 .Co-processed excipients for dispersible tablets-part 2: patient acceptability. J AAPS PharmSciTech, 19 : 2646-57.
Gohel M. .2005 .A review of co-processed directly compressible excipients. J Pharm Pharm Sci, 8(1) : 76-93.
Takeuchi Y. .2018 .Characterization of mannitol granules and powder: A comparative study using two flowability testers. International Journal of Pharmaceutics, 547(1-2) : 106-13.
Kokott M. .2021 .Evaluation of two novel coprocessed excipients for direct compression of orodispersible tablets and mini-tablets. European Journal of Pharmaceutics Biopharmaceutics, 168 : 122-30.
Manchanda S. .2018 .Formulation additives used in pharmaceutical products: emphasis on regulatory perspectives and GRAS. Dosage form design considerations: Elsevier, : 773-831.
Yassin S. .2015 .The disintegration process in microcrystalline cellulose based tablets, part 1: influence of temperature, porosity and superdisintegrants. Journal of Pharmaceutical Sciences, 104(10) : 3440-50.
Maqbool U. .2025 .Development and characterisation of fast dispersible dimenhydrinate tablets: Compactional study and in-silico PBPK modeling. Plos one, 20(10) : e0334421.
Chandarana C. .2023 .Measurement of process capability of manufacturing process of Levetiracetam by applying concept of six sigma. Indian J Pharm Educ Res, 57(2) : 386-92.
Adekeye K. .2013 .Evaluating Process Capability Indices for some Quality Characteristics of a Manufacturing Process. Journal of Statistical and Econometric Methods, 2 : 105-14.
Bowles B. J. .2018 .Co-processed excipients for dispersible tablets-part 1: Manufacturability. , 19(6) : 2598-2609.
0

Citations

0

Downloads

15

Views